"New Russia is catching up at an stellar speed on VC, research, new development and aiming at having global assets” – Fabrice Egros on BIO-2015
18 June 2015
NovaMedica has taken part in the Russian panel discussion on BIO-2015 in Philadelphia (USA). The session “Reaching Out to Russia: The Biotech R&D Landscape and Global Drug Discovery Case Studies. Emerging Opportunities in Global Markets” was organized by Skolkovo Foundation.
NovaMedica Starts its First Media Campaign
10 June 2015
Russian pharmaceutical company NovaMedica has started its first TV and Internet media campaign targeted at promotion of innovative gastroenterological products under an umbrella brand “Benegast”. Media campaign includes rotation of video commercials produced by BAZELEVS, a movie company owned by a famous director Timur Bekmambetov.
NovaMedica and Ferring Pharmaceuticals bring innovative gastroenterological products from Switzerland to Russia
02 June 2015
NovaMedica, a Russian pharmaceutical company, and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.
NovaMedica is Expanding Ophta Horizons
27 May 2015
NovaMedica, a Russian pharmaceutical company, participated in the White Nights-2015 International Ophthalmology Congress and hosted a satellite symposium “NovaMedica: New Ophta Horizons”. The symposium was started by Boris Malyugin, Deputy General Director for Science at MNTK “Eye Microsurgery” named after Federov S.N., and presented the first publication of in vitro research results on potency of netilmicin and reference drug products.
People, medicines and venture investments
13 April 2015
April 6-10, 2015, Moscow hosted the 22nd Russian National Congress “People and Medicines”. NovaMedica have actively participated in R&D part of its program and organized a symposium “Venture investments in Research and Development” chaired by Mikhail Getman, Vice President for Pharmaceutical Operations at NovaMedica.
NovaMedica helps ophthalmologists getting new knowledge
20 March 2015
NovaMedica participated in the annual conference “The 14th All-Russian Ophthalmologist School 2015” near Moscow. The event welcomed more than 200 medical specialist from all over Russia. The opinion leaders’s reports and presentations covered various issues of therapeutical and surgical ophtalmology.
Sergey Beloborodov: Produce locally, think globally
12 March 2015
“The production strategies based only on import substitutule won’t last for long,” noted Sergey Beloborodov, the Ecexutive Director of NovaMedica at the round-table discussion “Attracting investments to pharmaceutical industry” held during the InvestRus International Conference in Moscow March 11, 2015.
Omega Pharma and NovaMedica to market a line of gastrointestinal products under BenegastTM brand in Russia
22 January 2015
Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the BenegastTM umbrella brand in Russia.
Horus Pharma and NovaMedica sign agreement to market a portfolio of eye care products in Russia
25 September 2014
NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS).
Vladimir Gurdus to speak about latest developments of RusnanoMedInvest and NovaMedica projects at 20th Pharmaceutical Forum in St. Petersburg
18 June 2014
“We have worked our way up from the concept of RusnanoMedInvest portfolio building to first sales of NovaMedica pharmaceutical company within two years’ time. This pace of development is considered fast in the pharmaceutical industry”, - Vladimir Gurdus, CEO, RMI Partners, Management Company of RusnanoMedInvest (RMI) and NovaMedica said during his speech at 20th Russian Pharmaceutical Forum in St. Petersburg.
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
A resource for anti-tumor drugs testing has been launched in Russia
23 March 2023
Building a Community of Trust in Epilepsy & Rare Syndromes
23 March 2023
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
22 March 2023